Journal
JOURNAL OF CONTROLLED RELEASE
Volume 139, Issue 3, Pages 190-196Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2009.07.003
Keywords
Fibrinolysis; Thrombosis; Erythrocyte; Delivery vehicle; Urokinase
Funding
- PENN Institute for Translational Medicine and Therapeutics
- PENN Research Foundation Award
- Fondo de Investigaciones Sanitarias [P1081795]
- Spanish Ministry of Health and Consumer Affairs
- Pro-CNIC Foundation
- [HL076406]
- [NS053410]
- [HD57355]
- [HL081864]
- [HL66442]
- [HL090697]
Ask authors/readers for more resources
Coupling plasminogen activators to carrier red blood cells (RBC) prolongs their life-time in the circulation and restricts extravascular side effects, thereby allowing their utility for short-term thromboprophylaxis. Unlike constitutively active plasminogen activators, single chain urokinase plasminogen activator (scuPA) is activated by plasmin proteolysis or binding to its receptor, uPAR. In this study we conjugated recombinant soluble uPAR (suPAR) to rat RBC, forming RBC/suPAR complex. RBC carrying suPAR circulated in rats similarly to naive RBC and markedly prolonged the circulation time of suPAR. RBC/suPAR carrying similar to 3 x 10(4) suPAR molecules per RBC specifically bound up to 2 x 10(4) molecules of scuPA, retained similar to 75% of scuPA-binding capacity after circulation in rats and markedly altered the functional profile of bound scuPA. RBC carrying directly conjugated scuPA adhered to endothelial cells, while showing no appreciable fibrinolytic activity. In contrast, RBC/suPAR loaded with scuPA did not exhibit increased adhesion to endothelium, while effectively dissolving fibrin clots. This molecular design, capitalizing on unique biological features of the interaction of scuPA with its receptor, provides a promising modality to deliver a pro-drug for prevention of thrombosis. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available